Virtual Library

Start Your Search

H. Loubna



Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      208P - Metastatic non-small cell lung carcinoma: About 420 cases (ID 639)

      12:30 - 13:00  |  Presenting Author(s): H. Loubna

      • Abstract

      Background:
      Non-small cell lung carcinoma NSCLC is the leading cause of cancer death in the world. Its incidence is closely related to smoking. The prognosis of metastatic NSCLC remains poor despite major therapeutic advances.

      Methods:
      This is a descriptive retrospective study of patients treated for metastatic non-small cell lung carcinoma in the medical oncology department of HASSAN II University Hospital of Fez, over a period of 10 years, from January 2007 to July 2017.

      Results:
      420 cases have been identified. The average age of our patients was 58.63 years old [31–86]. The male sex was dominant with a percentage of 86%. Smoking was found in 76.1% of patients while occupational exposure to a risk factor was reported in 4% of cases. The disease is declared by cough in 45% of cases. Adenocarcinoma represents 47.1% of all histological subtypes. Most patients (62%) had a performance status that exceeded 1. The most frequent metastatic site was lung (45% of cases) followed by bone (28% of cases). 66% of patients received platinum based first line chemotherapy associated with Bevacizumab in non-squamous cell carcinomas. 30% of cases who had an EGFR mutation research had a mutation and received Erotinib or Afatinib. None of the patients was tested for ALK rearrangement or PDL 1 overexpression. 19% of cases received second-line systemic treatment with Docetaxel in 79.7% of cases, Pemetrexed in 17.5% and Erlotinib in 2.7% of cases. The overall response rate after first treatment line was 42%: 4% partial response, 38% stability and 56% progression. Whereas 75% of patients with tyrosine kinase inhibitors responded. After a median follow-up of 48 months, the median SSP and SG were 5.3 months and 11.2 months, respectively.

      Conclusions:
      The results of our series confirm the poor prognosis of metastatic NSCLC and emphasizes the need of implementing early diagnosis strategies and smoking quit in our country

      Clinical trial identification:
      Background : Non-small cell lung carcinoma NSCLC is the leading cause of cancer death in the world. Its incidence is closely related to smoking. The prognosis of metastatic NSCLC remains poor despite major therapeutic advances. Method : This is a descriptive retrospective study of patients treated for metastatic non-small cell lung carcinoma in the medical oncology department of HASSAN II University Hospital of Fez , over a period of 10 years, from January 2007 to July 2017. Results : 420 cases have been identified. The average age of our patients was 58.63 years old [31-86]. The male sex was dominant with a percentage of 86%. Smoking was found in 76.1% of patients while occupational exposure to a risk factor was reported in 4% of cases. The disease is declared by cough in 45% of cases. Adenocarcinoma represents 47.1% of all histological subtypes. Most patients (62%) had a performance status that exceeded 1. The most frequent metastatic site was lung (45% of cases) followed by bone (28% of cases). 66% of patients received platinum based first line chemotherapy associated with Bevacizumab in non squamous cell carcinomas. 30 % of cases who had an EGFR mutation research had a mutation and received Erotinib or Afatinib. None of the patients was tested for ALK rearrangement or PDL 1 overexpression. 19% of cases received second-line systemic treatment with Docetaxel in 79.7% of cases, Pemetrexed in 17.5% and Erlotinib in 2.7% of cases. The overall response rate with chemotherapy was … Whereas 75% of patients with tyrosine kinase inhibitors responded. After a median follow-up of 48 months, the median SSP and SG were 5.3 months and 11.2 months, respectively. Conclusion : The results of our series confirm the poor prognosis of metastatic NSCLC and emphasizes the need of implementing early diagnosis strategies and smoking quit in our country

      Legal entity responsible for the study:
      Department of Medical Oncology, HASSAN II University Hospital-Fez

      Funding:
      Has not received any funding

      Disclosure:
      All authors have declared no conflicts of interest.